Policy & Regulation
TRI commences ETHIC trial to evaluate potential benefits of early administration of LMWH in patients with COVID-19
30 June 2020 -

Thrombosis Research Institute (TRI) stated on Tuesday that it will launch an open-label randomized controlled trial of community-based early thromboprophylaxis named ETHIC (Early Thromboprophylaxis in COVID-19) under an investigator initiated grant from Sanofi.

The company added that the study was designed in response to recent evidence suggesting that severe COVID-19 infections are associated with increased frequency of thrombosis. The eligible patients will have newly-diagnosed Covid-19 under an increased risk of complications of infection due to age and comorbidities. The clinical trial will recruit approximately 1400 patients in ten countries starting in July.

As part of the trial, the symptomatic patients with COVID-19 receiving the low molecular weight Heparin enoxaparin and will be compared with patients receiving the standard of care. The follow up period for assessing outcomes including hospitalization and mortality is at 21 days, with further assessments at 50 days and 90 days.

Thrombosis Research Institute is a leader in innovative solutions for the detection and treatment of thrombosis. Sanofi is a global biopharmaceutical company focused on improving human health. Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system.